A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2004
12/09/2004	US20040248881 such as 1-[2-(2-chloro-phenyl)-3-(4-fluoro-phenyl)-2H-pyrazolo[3,4-d]pyridazin-7-yl]-4-isopropylamino-piperidine-4-carboxylic acid amide; for treatment of eating disorders and psychological disorders
12/09/2004	US20040248878 Lactam compound
12/09/2004	US20040248868 Antiischemic agents; prevent damage to tissues, organs
12/09/2004	US20040248843 Process for the preparation of tablets comprising s-adenosylmethionine
12/09/2004	US20040248829 Gene expression in embryonic pancreas cells, adipocytes; prevent metabolic disorders; antidiabetic agents; obesity; eating disorders; neurodegenerative disorders
12/09/2004	US20040248819 Administering fructose of fructose containing oligosaccharide
12/09/2004	US20040248806 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same
12/09/2004	US20040248790 eating regulator, a sleep regulator,.an arousal regulator, a pain regulator, a stress response regulator, a spontaneous behavior regulator or an emotional behavior regulator
12/09/2004	US20040248771 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
12/09/2004	US20040248767 Modulating serum amyloid a interaction with tanis and agents useful for same
12/09/2004	US20040248766 Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
12/09/2004	US20040248321 Membrane protein for use in treatment and prevention of inflammatory, circulatory, cell proliferative, metabolic and immunological disorders
12/09/2004	US20040248278 Streptococcus expressing lymphocytic protein for use in prevention and treatment of insulin resistance, obesity, autism and attention deficit/hyperactivity disorders
12/09/2004	US20040248252 Nucleotide sequences coding mammalian histamine H4 receptor protein for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders
12/09/2004	US20040248251 Receptors and membrane associated proteins
12/09/2004	US20040248249 Protein for use in treatment, prevention and diagnosis of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders
12/09/2004	US20040248247 Helix-loop-helix (BHLH) motif and a per-rrnt-sim homology domain (pas domain) (BHLH-PAS) protein for use in identifying modulators for diagnosis, prevention and treatment of retardation and nervous system disorders
12/09/2004	US20040248243 Lipid metabolizing polypeptide for use in identifying modulators for treatment and prevention of cancer, nervous system, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders
12/09/2004	US20040248240 Nucleotide sequences coding membrane protein for use in identifying modulator for treatment of pain management, epilepsy, stroke, ischemia and heart disease
12/09/2004	US20040248233 Using propyl hydroxylase expression system to identify modulators which interfere with or prevent generation of hypoxic states; screening modulator for treatment and prevention of cell proliferative and thrombotic disorder
12/09/2004	US20040248231 Using reduction in beta site amyloid precursor protein cleaving enzyme activity, manifested as decreased beta amyloid peptides production, as diagnostic indicator of enzyme inhibition; for use in treatment of amyloid deposition disorders
12/09/2004	US20040248208 Screening method
12/09/2004	US20040248207 Sodium channel regulators and modulators
12/09/2004	US20040248188 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/09/2004	US20040248178 Nucleotide sequences coding neuronal outgrowth and stability protein for use in treating ovarian, renal, neurological, cell proliferative and cardiovascular disorders
12/09/2004	US20040248173 Nucleotide sequences coding cyclic peptide receptor for use in identifying modulators for treatment of pituitary hormone, epinephrine release, gastrointestinal, cardiovascular, electrolyte balance, hypertensive, diabetic and respiratory system disorder
12/09/2004	US20040248137 Human and mammalian stem cell-derived neuron survival polypeptides
12/09/2004	US20040247716 Composition containing asiasari radix extracts for protecting brain cells and improving memory
12/09/2004	US20040247703 Composition for inhibiting glutamate-mediated neurotoxicity comprising ginsenoside Rg3 or ginsenoside Rh2
12/09/2004	US20040247612 Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease
12/09/2004	US20040247604 Anti-inflamatory fatty alcohols and fatty acid esters useful as antigen carriers
12/09/2004	US20040247581 Bacterial strains that adhere to intestinal gut (capability to adhere to the cell lines Caco-2 or Hep-2) and lowering the concentration of pathogenic peptides (measured as peptidase activity), used to treat behavioral or psychiatric disorders, such as autism, ADHD, mood disorders, and schizophrenia
12/09/2004	US20040247571 Neural cells expressing tyrosine hydroxylase
12/09/2004	CA2527431A1 Deramciclane-fumarate tablets
12/09/2004	CA2527354A1 Compounds useful in the therapy of alzheimer`s disease and formulations containing them
12/09/2004	CA2527194A1 Novel ureido - and amido-pyrazolone derivatives
12/09/2004	CA2527174A1 Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
12/09/2004	CA2527159A1 3-aminomethyl-pyrrolidines as n-type calcium channel blockers
12/09/2004	CA2527145A1 Use of iron for treating attention deficit hyperactivity disorder in children
12/09/2004	CA2527094A1 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
12/09/2004	CA2527039A1 Grf analog compositions and their use
12/09/2004	CA2526695A1 Selection of allosteric regulators with class iii g protein-coupled receptors depleted of the extracellular domain
12/09/2004	CA2525282A1 Indole derivatives with an improved antipsychotic activity
12/09/2004	CA2514121A1 Composition possessing autonomic nerve function regulating action and use thereof
12/08/2004	EP1484400A1 Sodium-independent transporter carrying acidic amino acid and its gene
12/08/2004	EP1484333A1 New aminopropylphosphonous acids
12/08/2004	EP1484330A1 Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
12/08/2004	EP1484327A1 Nitrogenous heterocyclic compound and medicine thereof
12/08/2004	EP1484320A1 Jnk inhibitor
12/08/2004	EP1484057A1 Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
12/08/2004	EP1484053A2 Percutaneously applicable preparation and suppository containing an antidementia medicament
12/08/2004	EP1483588A2 Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
12/08/2004	EP1483266A1 Spiro compounds with npy antagonistic activity
12/08/2004	EP1483265A1 Purine derivatives as kinase inhibitors
12/08/2004	EP1483263A1 Thiazolyl urea compounds for the treatment of cancer
12/08/2004	EP1483260A1 Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
12/08/2004	EP1483247A2 Aryl substituted pyrimidines and the use thereof
12/08/2004	EP1483244A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase
12/08/2004	EP1483243A1 PREPARATION OF N1-(2’-PYRIDYL)-1,2-PROPANEDIAMINE SULFAMIC ACID AND ITS USE IN THE SYNTHESIS OF BIOLOGICALLY ACTIVE PIPERAZINES
12/08/2004	EP1483237A2 Tropane compounds
12/08/2004	EP1483236A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists
12/08/2004	EP1483228A1 Nk1 antagonists
12/08/2004	EP1482984A2 Surrogate antibodies and methods of preparation and use thereof
12/08/2004	EP1482983A2 Non-myeloablative tolerogenic treatment with tyrphostins
12/08/2004	EP1482973A1 Methods of modulating cd200 receptors
12/08/2004	EP1482972A2 Treatment of immunological disorders using anti-cd30 antibodies
12/08/2004	EP1482962A2 Method of treating trx mediated diseases
12/08/2004	EP1482955A1 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
12/08/2004	EP1482952A2 Therapeutic and prophylactic treatment of aging and disorders of aging in humans
12/08/2004	EP1482951A1 Alpha-hydroxy-2-methylene-10-nor-pregnacalciferol and its uses
12/08/2004	EP1482950A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
12/08/2004	EP1482945A1 Crystalline forms of quetiapine hemifumarate
12/08/2004	EP1482939A1 Preparation of paroxetine involving novel intermediates
12/08/2004	EP1482937A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
12/08/2004	EP1482934A1 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases
12/08/2004	EP1482931A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/08/2004	EP1482928A2 Mediators of hedgehog signaling pathways,compositions and uses related thereto
12/08/2004	EP1482926A2 Amino-methyl substituted tetracycline compounds
12/08/2004	EP1482921A1 Methods of treating attention deficit/hyperactivity disorder (adhd)
12/08/2004	EP1482920A1 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
12/08/2004	EP1482916A2 Schwann cell and phosphodiesterase inhibitors based therapy
12/08/2004	EP1482896A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482895A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482787A2 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
12/08/2004	EP1434886A4 Mid 241 receptor, a novel g-protein coupled receptor
12/08/2004	EP1412341B1 Process for the preparation of racemic citalopram and/or s- or r-citalopram by separation of a mixture of r- and s-citalopram
12/08/2004	EP1381363B1 Imidazo [1,2-a]-pyridine derivatives as mglur5 antagonists
12/08/2004	EP1363898A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
12/08/2004	EP1341754B1 Substituted anthranilic acids
12/08/2004	EP1339403B1 Repinotan kit
12/08/2004	EP1251120B1 Esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl
12/08/2004	EP1230205B1 Method for producing compounds of the valproinic acid
12/08/2004	EP1220856B1 Pyrazolo[4,3-d]pyrimidine derivatives
12/08/2004	EP1210118B1 Composition comprising a tramadol material and an anticonvulsant drug
12/08/2004	EP1149102B1 Triazolo-pyridazine derivatives as ligands for gaba receptors
12/08/2004	EP1127052B1 Substituted 2-phenylbenzimidazoles, the production thereof and their use
12/08/2004	EP1125135B1 A complex of a chaperone with beta-amyloid and methods employing this complex
12/08/2004	EP1121354B1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h 3 agonists or antagonists
12/08/2004	EP1119548B1 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
12/08/2004	EP0812190B1 R-enantiomer of n-propargyl-1-aminoindan for the treatment of various diseases and mesylate, esylate and sulfate thereof

1 ... 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 ... 1833